162 related articles for article (PubMed ID: 11828840)
1. Current status of the drug safety monitoring system in Korea.
Park BJ
Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
[No Abstract] [Full Text] [Related]
2. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
3. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
4. [Regulatory guidelines and drug safety].
Flury W
Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing drug dosage changes.
Peck CC
Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120
[No Abstract] [Full Text] [Related]
6. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
7. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
8. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
9. [Comparative organization of drug monitoring in France and 7 European countries].
Vaissere J; de Cremiers F; Auriche M; Juillet Y
Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
[No Abstract] [Full Text] [Related]
10. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
Rawson NS; West R; Appel WC
Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
12. [The Spanish drug surveillance system].
Laporte JR; Capellà D
Med Clin (Barc); 1994 Sep; 103(9):335-6. PubMed ID: 7967892
[No Abstract] [Full Text] [Related]
13. [Unwanted drug interactions. Keeping up pharmacovigilance using databases].
Schindler B
Med Monatsschr Pharm; 2008 Apr; 31(4):155-6. PubMed ID: 18497254
[No Abstract] [Full Text] [Related]
14. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
15. Drug safety and regulation.
Waller PC; Evans SJ; Beard K
BMJ; 2005 Jul; 331(7507):4-5. PubMed ID: 15994664
[No Abstract] [Full Text] [Related]
16. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
Haramburu F; Pere JC; Begaud B; Albin H
Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
[No Abstract] [Full Text] [Related]
17. [4-year experience in drug surveillance].
Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
[No Abstract] [Full Text] [Related]
18. Should new drugs be avoided?
Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
[No Abstract] [Full Text] [Related]
19. [Drug safety. Notes about surveillance].
Moreno Alvarez PJ; Madurga Sanz M
Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
[No Abstract] [Full Text] [Related]
20. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
